CYP19A1 Antibody

Code CSB-RA006394A0HU
Size US$350
Image
  • Western Blot
    Positive WB detected in: HepG2 whole cell lysate, Jurkat whole cell lysate, 293 whole cell lysate, SH-SY5Y whole cell lysate, U87 whole cell lysate, K562 whole cell lysate
    All lanes: CYP19A1 antibody at 2.3μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 58, 25 KDa
    Observed band size: 58 KDa

  • IHC image of CSB-RA006394A0HU diluted at 1:230 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescence staining of HepG2 cells with CSB-RA006394A0HU at 1:76, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L).

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P11511
Target Names CYP19A1
Alternative Names ARO antibody; ARO1 antibody; Aromatase antibody; CP19A_HUMAN antibody; CPV1 antibody; CYAR antibody; CYP19 antibody; Cyp19a1 antibody; CYPXIX antibody; Cytochrome P-450AROM antibody; Cytochrome P450 19A1 antibody; Cytochrome P450; family 19; subfamily A; polypeptide 1 antibody; Cytochrome P450; subfamily XIX (aromatization of androgens) antibody; Estrogen synthase antibody; Estrogen synthetase antibody; Flavoprotein linked monooxygenase antibody; MGC104309 antibody; Microsomal monooxygenase antibody; OTTHUMP00000162543 antibody; OTTHUMP00000198350 antibody; P 450AROM antibody
Species Reactivity Human
Immunogen A synthesized peptide derived from human CYP19A1
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Monoclonal
Isotype Rabbit IgG
Purification Method Affinity-chromatography
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form Liquid
Tested Applications ELISA, WB, IHC, IF
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
IF 1:20-1:200
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene References into Functions
  1. Polymorphism in CYP19A1 is not associated with polycystic ovary syndrome. PMID: 29564739
  2. CYP19A1 was the only gene harboring single nucleotide polymorphisms that were significantly associated with prostate cancer risk PMID: 29228205
  3. CYP19A1 mRNA expression and aromatase activity during syncytialization of primary human villous trophoblast cells at term PMID: 29474975
  4. in postmenopausal women, aromatase activity could be an important determinant of skeletal health. PMID: 29329467
  5. Fungicide ziram may disrupt the placental steroid production. In the present study, we investigated the effects of ziram on steroid formation in human placental cell line JEG-3 cells and on HSD3B1 and aromatase in the human placenta. Ziram did not inhibit progesterone production in JEG-3 cells and HSD3B1 activity at 100muM... ziram is a potent inhibitor of human aromatase. PMID: 28951168
  6. This study demonstrated the existence of an AMH-FOXL2 relationship in hGCs. AMH is capable of increasing both gene and protein expression of FOXL2. Because FOXL2 induces AMH transcription, these ovarian factors could be finely regulated by a positive feedback loop mechanism to preserve the ovarian follicle reserve. PMID: 28660501
  7. The present study reports on the synthesis of pituitary aromatase, its regulation by gonadal steroids, and the physiological roles of aromatase on pituitary endocrine cells. The involvement of aromatase in the pathogenesis of pituitary tumors, mainly prolactinomas, through the auto-paracrine production of estradiol is reviewed. [review] PMID: 29104246
  8. CYP19A1 Val80, a genetic polymorphism related to the conversion of testosterone into estrogen, significantly contributes to individual differences in self-construal and subjective well-being. PMID: 28888137
  9. The findings indicate that the CYP19 alleles rs727479A/C and rs700519C/T might be associated with the pregnancy outcome after assisted reproductive technology in patients with polycystic ovary syndrome. PMID: 29050673
  10. significant prognostic roles of ERalpha, ERbeta and aromatase were discovered in the in prostate cancer specimens of our large multicenter cohort. PMID: 27610593
  11. These studies suggest an association between adiposity, aromatase estrogenic capacity and atrial arrhythmogenicity. PMID: 28822806
  12. Changes in the CYP19A1 expression in adipose tissue stromal vascular fraction cells, induced by free acids, correlated positively with BMI of patients but only in group of obese or overweight women. PMID: 29629743
  13. In conclusion, activated Smad3 proteins can bind to P450arom promoter -705/+87 bp region, responsive to activin A in endometrial stromal cells, which can promote P450arom transcription. PMID: 27920344
  14. polymorphisms not associated with late miscarriage PMID: 28410957
  15. this study illustrated that the brain-specific alternate promoter PI.f derived CYP19 expression can be regulated by DNA methylation. PMID: 28559115
  16. sex steroid hormones and sex hormone binding globulin levels, CYP17 MSP AI (-34T:C) and CYP19 codon 39 (Trp:Arg) variants in children with developmental stuttering PMID: 28992603
  17. RET inhibitors could both impair primary tumor growth and tumor dissemination, thereby providing a potential therapeutic advantage when used in combination with aromatase inhibitors in postmenopausal ER+ breast cancers. PMID: 27602955
  18. We suggest from these studies that overexpression of aromatase in breast tissue and its resultant increase in estradiol levels may contribute to the later development of breast cancer in women with atypical ductal hyperplasia PMID: 28337664
  19. As regards the CYP19A1 variant, genotype 11 (del/del) was more frequent in patients than in controls (OR=1.85; 95% CI 1.06-3.22; P=0.03). PMID: 27145040
  20. C-Jun and CREB are recruited to ESR2 or CYP19A1 promoter by IGF-I stimulation. PMID: 26899323
  21. The results of the present study suggest that AhR stimulates estrogen-dependent progression of breast carcinoma by inducing aromatase expression under some conditions. These results provide new insights on the possible roles of environmental toxins in breast cancer development. PMID: 27900579
  22. In the postmortem study, the amount of PVN aromatase immunoreactivity decreased significantly in the major depressive disorder group compared to the controls PMID: 28024269
  23. Results show that aromatase protein expression is increased in bladder neoplasm tissue and may be associated with advanced tumor stage. PMID: 27324053
  24. Polymorphism of CYP19 is associated with breast cancer. PMID: 28178648
  25. The combination of high carbohydrate intake and the heterozygote (CG) of CYP19A1 rs4441215 showed a higher serum estradiol level in postmenopausal Japanese women. PMID: 28980890
  26. Leptin increased aromatase expression in breast cancer cells, which was correlated with COX-2 upregulation. PMID: 28571770
  27. Immunohistochemical analysis of 221 invasive breast cancer cases indicated that 87.3% (193/221) had at least 5% aromatase positive cells. PMID: 28489882
  28. CYP19A1 amplification caused increased aromatase activity. PMID: 28112739
  29. The reduction of DHT obese homozygotic twins could be linked to its increased degradation by AKR1C2 and HSD11B1, and increased estrogen levels could be linked to increased adiposity-related expression of aromatase in adipose tissue. PMID: 28619249
  30. The authors proposed that NF2 behaves as a protein sensing tissue damage and aromatase-driven local estrogen formation, eventually leading to regulation of stem cells differentiation and tissue repair by liver cancer cells. (Review) PMID: 27289045
  31. The CYP19A1 rs10046 variant T/T favors lower incidence of hot flashes/sweating under exemestane + OFS treatment, suggesting endocrine-mediated effects. PMID: 27825388
  32. R264 polymorphism causes an intrinsic alteration of aromatase activity together with a different consensus for phosphorylation by different kinases, indicating that estrogen production can be different when such mutations are present PMID: 27702664
  33. analysis of how sildenafil inhibits aromatase in human cells by molecular docking simulation PMID: 27616271
  34. 16(beta)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1 PMID: 28065637
  35. Description of a novel functional FSHR expression, where FSH-stimulated CYP19A1 expression and estrogen production in recto-vaginal endometriotic nodules (RVEN) are demonstrated. This locally FSH-induced estrogen production may contribute to the pathology, development, progression, and severity of RVEN . PMID: 27224263
  36. Estradiol synthesis in the hippocampus is regulated by several mechanisms, which are reviewed in this report. The regulation of the activity of aromatase, the final enzyme of estrogen biosynthesis, by Ca(2+) transients, is of particular interest. [review] PMID: 26472556
  37. CYP19A1 activity may contribute to disordered steroidogenesis in female patients with POR mutations as well as in mothers with POR variants carrying a male child PMID: 27032764
  38. The structural and functional importance of estrogen receptor and aromatase in endocrine-responsive and -resistant breast cancers will be discussed in more detail. [review] PMID: 26277097
  39. Aromatase inhibitor treatment significantly increased expression of let-7f in Ishikawa cells and endometrial stroma cells from patients with endometriosis. PMID: 27320036
  40. results show that the Aha1-Hsp90-PKM2/HIF-1alpha axis mediates the induction of aromatase in Li-Fraumeni Syndrome. PMID: 27467582
  41. Data show that the combination of nobiletin (NOB), hesperetin (HES) and letrozole (LET) had no effects on activity and expression of aromatase (cytochrome P450 CYP19) in MCF-7 breast cancer cells. PMID: 28364779
  42. The expression of P450 aromatase corresponds to specific cell morphology in sex cord-stromal tumors, including recurrent tumors. PMID: 26166720
  43. Association study investigated the ESR1, ESR2, and CYP19A1 gene polymorphisms in Chinese migraine patients, data suggested that ESR1 rs2234693 plays a potential role in migraine susceptibility in a Chinese population, especially for menstrually related migraine PMID: 27778160
  44. A novel 568C insertion mutation in CYP19A1 can lead to severe aromatase deficiency. Homozygosity for this mutation is associated with the development of hypoplastic ovaries PMID: 27086564
  45. Significant reduction of CYP19A1 gene expression in Cumulus cells of endometriosis patients may be the result of epigenetic alterations in its regulatory regions, either by DNA methylation or histone modifications. PMID: 27167072
  46. In the bone marrow, cyclin A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen and matrix metalloproteinase MMP9 and promoted the metastatic growth of prostate cancer cells PMID: 26921336
  47. No association of functional polymorphisms in the estrogen metabolism genes CYP19A1 with menstrual migraine. PMID: 28089731
  48. The results demonstrated that the rs3751592 A/G polymorphism of the CYP19A1 gene was associated with the incidence of Alzheimer disease in a Chinese Han population, which suggests that CYP19A1 rs3751592 is a predisposing genetic factor for Alzheimer disease. PMID: 27583919
  49. CYP19 Gene Polymorphism is associated with Breast Cancer. PMID: 27165202
  50. The data showed that the effect of Activin A on ESCs was partially abrogated by pretreatment with an inhibitor of ALK4 (the type I receptor, ActRIB) and Smad4-siRNA. Cumulatively, these data suggest that Activin A promotes the secretion of estradiol from ESCs by increasing the expression of P450arom via the ALK4-Smad pathway. These findings indicate the ALK4-Smad pathway may promote ectopic lesion survival and developmen PMID: 27833918
  51. Results show downregulation of CYP19A1 mRNA level in postmenopausal invasive ductal cancer which correlates with tumor prognosis. PMID: 27365044
  52. Present meta-analysis reveals that CYP19 rs10046 polymorphism may be not correlated to endometriosis risk. PMID: 26897397
  53. results indicated that there was a significant association between migraine and gene-gene interaction among the CYP19A1, FSHR, ESR1 and NRIP1. PMID: 27019440
  54. The new controls of aromatase function provide insights into the mechanisms through which local estrogen production can be altered in breast cancer tissues. PMID: 26996624
  55. In the present study we assessed whether genetic variation in CYP19A1 is associated with risk of BC in a case-control study group nested within the Danish "Diet, Cancer and Health" cohort (ncases = 687 and ncontrols = 687) and searched for gene-gene interaction between CYP19A1 and PPARGC1A, and CYP19A1 and PPARG, and gene-alcohol and gene-NSAID interactions PMID: 27102200
  56. EGb 761 reduced the tumor size and significantly reduced tumor CYP19 mRNA expression. PMID: 26706698
  57. The CT genotype of the rs2289105 polymorphism in the CYP19 gene is associated with a decreased risk of CHD and may be a genetic marker of protection from CHD PMID: 26562495
  58. Metformin inhibits PGE2-induced CYP19A1 mRNA expression/aromatase activity via AMPK activation in endometriotic stromal cells. PMID: 26058395
  59. Higher CYP19A1 expression and E2 concentrations are associated with increased risk of endometrial cancer. PMID: 26574572
  60. study to determine distribution of CYP19(TTTA)n polymorphism in Mexican general population and search for associations of particular genotypes with hip fracture and lumbar spine osteoporosis; the A1 allele and the A1A1 genotype were associated with an elevated risk of fracture; the A2 allele was associated with protection of hip fracture as the A2A2 genotype PMID: 26426292
  61. The leptin, ObR and aromatase protein expression levels were increased in lesions in the vaginal septum and were decreased in the intestine lesions PMID: 26242176
  62. The CYP19A1 rs10046 polymorphism is associated with cardiovascular risk factors such as circulating apoB, insulin resistance and hypertension in a sex- and obesity-specific manner. PMID: 26415088
  63. The rs6493497 and rs7176005 SNPs of the CYP19A1 gene may be genetic markers that influence the risk of FPHL in this Chinese population. PMID: 26228318
  64. the relationship between CYP19 gene polymorphisms and breast cancer in Xinjiang Uigur women was investigated. PMID: 26345775
  65. Our findings suggested that CYP19A1 and HSD17B2 polymorphisms might be associated with circulating sex hormone levels in Japanese postmenopausal women, independent of current BMI. PMID: 26323233
  66. the hyperandrogenic follicular environment may be a key hazardous factor leading to the down-regulation of aromatase in polycystic ovary syndrome PMID: 26199450
  67. The PI3K/AKT/IKK and the mitogenactivated protein kinase pathways are involved in collagen and PGE2induced aromatase expression PMID: 26059638
  68. Our study demonstrated significant aromatase co-expression in growth hormone, prolactin, and thyroid stimulating hormone secreting cells of the human anterior pituitary gland. PMID: 25697985
  69. The study investigates the hydroxylation of the substrate androstenedione to 19-hydroxy-androstenedione, occurring during the first catalytic subcycle of CYP19A1. PMID: 26096372
  70. T allele of rs2289105 in CYP19 gene might be a protective genetic marker of essential hypertension for women in Han population. PMID: 27012050
  71. The homozygous minor allele (AA) of CYP19A1 rs4646 is significantly associated with improved clinical outcome of hormone therapy in premenopausal HR-positive early breast cancer patients, but with a worse impact on postmenopausal women. PMID: 26191232
  72. Patients with the GG genotype for the rs700518 polymorphism in the CYP19A1 gene are at risk for significant loss of fat-free mass and increase in truncal fat with aromatase inhibitor therapy. PMID: 26049585
  73. Variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high Native American ancestry. PMID: 25088806
  74. electron transfer between mCPR and aromatase PMID: 26087061
  75. CYP19 mRNA could be transcribed from a promoter in which chromatin is shifted toward an open state in the equilibrium between closed and open chromatin. PMID: 26020632
  76. oxidative step in the conversion of androgens to estrogens by cytochrome P450 19A1 steroid aromatase PMID: 25252141
  77. The present study indicates that CYP19 rs4646 polymorphism is related to disease-free survival in early breast cancer. PMID: 25793413
  78. results show reduced expression of the CYP19A1 in cumulus cells of infertile women with endometriosis, which may play a role in the pathogenesis of endometriosis-related infertility PMID: 25773531
  79. CYP19A1 rs700518 variants showed associations with BCFI, DRFI, in tamoxifen treated patients and musculoskeletal AEs regardless of treatment. SNPs rs4646, rs10046, and rs936308 were associated with bone AEs. PMID: 25935582
  80. The study demonstrates that differences in the allele frequencies of CYP19A1 intron single nucleotide polymorphisms are not consistent between populations of African and European ancestry. PMID: 25647083
  81. ARO1 is the key enzyme for estrogen biosynthesis, and its expression in the adipose stroma makes it a particularly interesting target in the context of estrogen receptor + breast cancers developing in obese women. [review] PMID: 26209254
  82. Two SNPs in CYP19A1, rs749292 and rs7172156, are associated with both daily oestrogen levels and mammographic density phenotypes. BMI may modify these associations. PMID: 25522654
  83. Polymorphic genetic variations of cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population PMID: 25481307
  84. The key enzymes of ovarian steroidogenesis, CYP 19 and 17beta-HSD, are active in the ovaries of postmenopausal women. PMID: 24855493
  85. This study indicates that obesity-associated systemic IL-6 indirectly enhances pre-adipocyte aromatase expression via increased breast cancer cell PGE2 production. PMID: 25476497
  86. Aromatase expression was lost in most pituitary adenomas, regardless of gender, tumor subtype, or tumor size. PMID: 25410472
  87. The protective effect of female gender on abdominal aortic aneurysms is due to estrogen synthesis and requires the presence of both ovarian and extragonadal/peripheral aromatase. PMID: 24582702
  88. two novel CYP19A1 missense mutations in an aromatase-deficient man PMID: 25301327
  89. Increased expression of aromatase P450 is associated with endometrial hyperplasia in polycystic ovary syndrome. PMID: 25374239
  90. Molecular analysis showed no association between sex hormone gene CYP19A1 and MtF transsexualism. Variable regions analysed are not associated with MtF. PMID: 25124466
  91. Aromatase overexpression in breast cancer tissues is likely to result from a promoter switch of CYP19A1 and/or accumulation of CYP19A1-expressing cells, rather than from cryptic transactivation of CYP19A1 because of genomic rearrangements at 15q21. PMID: 23625277
  92. Resonance Raman spectroscopy is used to characterize the active site structures of dioxygen adducts of CYP19A1 bound with the first androstenedione (AD) or third (19-oxo-AD) substrates encountered in the enzymatic cycle. PMID: 24645879
  93. study found carriers of a higher repeat (TTTA) polymorphism in intron 4 of CYP19A1 gene had higher levels of oestrogen; Those carrying the (TTTA) repeat allele may have a higher risk of developing central precocious puberty PMID: 24612204
  94. To our knowledge, this work represents the first experimental assignment of a pK(a) value to a residue in a cytochrome P450 (CYP19A1) PMID: 25425647
  95. Overall, our results demonstrate that p53 is a negative regulator of aromatase in the breast and its inhibition by PGE2 provides a novel mechanism for aromatase regulation in obesity and breast cancer. PMID: 25634217
  96. risk of menopause entry in European-American smokers varies depending on genetic background PMID: 24448104
  97. Aromatase is a candidate prognostic factor in patients with lung adenocarcinoma, especially in those with EGFR mutations, and may also be a beneficial therapeutic target in those patients. PMID: 24803578
  98. These results suggest that estradiol concentration is locally increased in human interstitial pneumonia tissue by aromatase. PMID: 24861259
  99. The (TTTA)n polymorphism of the CYP19 gene is associated with spinal BMD in peri- and postmenopausal Greek women. PMID: 24621381
  100. Epistatic interaction between IL10 rs1800896 and aromatase (CYP19A1) rs1062033 in Alzheimer disease risk in women. PMID: 23736221

Show More

Hide All

Involvement in disease Aromatase excess syndrome (AEXS); Aromatase deficiency (AROD)
Subcellular Location Membrane, Peripheral membrane protein
Protein Families Cytochrome P450 family
Tissue Specificity Widely expressed, including in adult and fetal brain, placenta, skin fibroblasts, adipose tissue and gonads.
Database Links

HGNC: 2594

OMIM: 107910

KEGG: hsa:1588

STRING: 9606.ENSP00000260433

UniGene: Hs.260074

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1